Tagged with R

Germany Establishing a genuine European investment promotion platform is central. Understanding ourselves as strong nations is probably the most important shift needed over the next few years. Achim Hartig, Director of Foreign Direct Investment at Germany Trade & Invest (GTAI) and Chair of the OECD Network of Investment Promotion Agencies, discusses…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius signing a US$ 322M deal with Sandoz, and KeyMed proposing a STAR Market listing. Clinical highlights feature Sunshine Guojian’s NMPA…

Korea Yeul Hong Kim, R&D President of Yuhan, discusses the company’s transformation from a traditional Korean pharmaceutical business into an increasingly global innovator. He outlines Yuhan’s open innovation strategy, pipeline focus, investment in new modalities and AI-driven discovery, and its approach to global partnerships. Kim also discusses Korea’s pharmaceutical landscape, pricing…

Germany Demand for plasma-derived medicines continues to rise, bringing renewed attention to manufacturing capacity, supply resilience and the need for stronger plasma ecosystems. As Biotest enters its next phase of growth, CEO Jörg Schüttrumpf reflects on the company’s strategic evolution, the opportunities created by its partnership with Grifols, and the role…

Europe Leadership in today’s pharmaceutical industry is no longer defined solely by the strength of a pipeline, but by the ability to anticipate change, execute consistently and adapt at scale. As Europe rethinks the balance between affordability, resilience and innovation, Michal Nitka, SVP, Head Generics Europe & Global Head OTC at…

Europe Rock-bottom prices, regulatory red tape, and intense competition from Asia have made life difficult for Europe’s generics and biosimilar producers. Yet a handful of companies are not just surviving this squeeze but thriving in it – through diversification, geographic focus, R&D intensity, or sheer scientific specialisation. Here’s how four of…

China Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors through the data gaps, bridging studies, and regulatory quirks that stand between a China-developed drug and a Western marketing authorisation.…

USA Joshua Salsi, Head of North America, Biocon Biologics explains the company’s evolution into an integrated, global biosimilars company following the 2022 Viatris portfolio reacquisition. He highlights the company’s growing US leadership, expanding pipeline, vertical integration, and focus on patient access. Salsi goes on to stresses that long-term biosimilar growth depends…

USA Pamela Gavin, CEO of the National Organization for Rare Disorders, discusses NORD’s origins in the advocacy movement that led to the Orphan Drug Act and its current mission to improve diagnosis, care, research, and policy for rare disease patients. She highlights the growing role of patient-led research, the need for…

USA Daniel Camardo is the President of Immedica Pharma US Inc. (Immedica), the US affiliate/subsidiary of Immedica Pharma AB, a Sweden-based rare disease company that entered the American market in 2024. Bringing together his experience building Astellas’s US presence and leading rare disease commercialization at Horizon, Camardo joined Immedica to lead…

USA Gilmore O’Neill, CEO of Editas Medicine, reflects on the company’s evolution from CRISPR pioneer to focused in vivo therapeutics developer. Two years into a strategic pivot, O’Neill shares the reasoning behind discontinuing the reni-cel cell therapy program in favor of lipid nanoparticle-delivered gene editing, and how EDIT-401, targeting severe hyperlipidemia,…

Taiwan Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI contrast agent for liver cancer, and MPT 1734, a nanomicelle-based therapy for prostate cancer, while outlining MegaPro’s partnership strategy, cell-tracking…